SCHEMBL2875665

SCHEMBL2875665

O=C(Cc1ccc(F)cc1)NC(Cc1ccccc1)C1CCCCC1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EPHX2 P34913 1/20 0.53
CNR2 P34972 3/20 0.53
ALDH1A1 P00352 3/20 0.51
KDM4E B2RXH2 2/20 0.51
CYP3A4 P08684 1/20 0.51
CYP2D6 P10635 1/20 0.51
CYP2C9 P11712 1/20 0.51
CYP2C19 P33261 1/20 0.51
SIGMAR1 Q99720 2/20 0.51
RAB9A P51151 1/20 0.49
MEN1 O00255 1/20 0.47
KMT2A Q03164 1/20 0.47
CCR3 P51677 2/20 0.46
TDP1 Q9NUW8 1/20 0.46
PSMB8 P28062 1/20 0.45
PSMB5 P28074 1/20 0.45
HTT P42858 1/20 0.45
AGER Q15109 2/20 0.44
LMNA P02545 1/20 0.44
POLB P06746 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2877086 0.92 EPHX2 (0.61) EPHX2CNR2ALDH1A1CYP3A4RAB9A
SCHEMBL2861732 0.86 EPHX2 (0.62) EPHX2CNR2ALDH1A1CYP3A4CYP2D6
SCHEMBL2863165 0.80 ALDH1A1 (0.54) EPHX2ALDH1A1CYP2C19RAB9APOLB
SCHEMBL2857888 0.78 PSMB5 (0.52) ALDH1A1RAB9APSMB5
SCHEMBL2864934 0.78 TSHR (0.49) EPHX2KMT2ATDP1PSMB5
SCHEMBL2861620 0.77 CTRB1 (0.51) EPHX2ALDH1A1RAB9ATDP1
SCHEMBL2861403 0.77 L3MBTL1 (0.49) EPHX2ALDH1A1RAB9ATDP1PSMB5
SCHEMBL8109196 0.76 PSMB8 (0.43) EPHX2CNR2ALDH1A1CYP3A4CYP2D6
SCHEMBL2857264 0.76 PYGL (0.46) CNR2RAB9AKMT2APSMB5POLB
SCHEMBL23642933 0.76 PSEN1 (0.51) EPHX2CNR2ALDH1A1KDM4ECYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2253328-A1 Cycloalkyl inhibitors of potassium channel function Bristol-Myers Squibb Company (US) 2010-11-24 EP disclosed
US-20070142333-A1 CYCLOALKYL INHIBITORS OF POTASSIUM CHANNEL FUNCTION BRISTOL-MYERS SQUIBB COMPANY 2007-06-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070142333-A1 CYCLOALKYL INHIBITORS OF POTASSIUM CHANNEL FUNCTION KCNJ2, KCNN3, KCNQ5 EPHX2 4474/4885CNR2 1504/4885ALDH1A1 4075/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.